Article
Fine-tuning of MEK signaling is pivotal for limiting B and T cell activation.
Cell reports - 11 Jan 2022
Houde Nicolas, Beuret Laurent, Bonaud Amélie, Fortier-Beaulieu Simon-Pierre, Truchon-Landry Kim, Aoidi Rifdat, Pic Émilie, Alouche Nagham, Rondeau Vincent, Schlecht-Louf Géraldine, Balabanian Karl, Espéli Marion, Charron Jean
Abstract excerpt
MEK1 and MEK2, the only known activators of ERK, are attractive therapeutic candidates for both cancer and autoimmune diseases. However, how MEK signaling finely regulates immune cell activation is only partially understood. To address this question, we specifically delete Mek1 in hematopoietic cells in the Mek2 null background. Characterization of an allelic series of Mek mutants reveals the presence of distinct...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
